A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Open Access
- 5 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (27) , e38754
Abstract
The current first-line treatment for atherosclerotic cardiovascular disease (ASCVD) involves the reduction of a patient’s low-density lipoprotein cholesterol (LDL-C) levels through the use of lipid-lowering drugs. However, even when other risk factors such as hypertension and diabetes are effectively managed, there remains a residual cardiovascular risk in these patients despite achieving target LDL-C levels with statins and new lipid-lowering medications. This risk was previously believed to be associated with lipid components other than LDL, such as triglycerides. However, recent studies have unveiled the crucial role of remnant cholesterol (RC) in atherosclerosis, not just triglycerides. The metabolized product of triglyceride-rich lipoproteins is referred to as triglyceride-rich remnant lipoprotein particles, and its cholesterol component is known as RC. Numerous pieces of evidence from epidemiological investigations and genetic studies demonstrate that RC plays a significant role in predicting the incidence of ASCVD. As a novel marker for atherosclerosis prediction, when LDL-C is appropriately controlled, RC should be prioritized for attention and intervention among individuals at high risk of ASCVD. Therefore, reducing RC levels through the use of various lipid-lowering drugs may yield long-term benefits. Nevertheless, routine testing of RC in clinical practice remains controversial, necessitating further research on the treatment of elevated RC levels to evaluate the advantages of reducing RC in patients at high risk of ASCVD.Keywords
This publication has 57 references indexed in Scilit:
- Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortalityAtherosclerosis, 2023
- Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular DiseaseCurrent Atherosclerosis Reports, 2022
- Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiographyAtherosclerosis, 2019
- Remnant-like particles and coronary artery disease in familial hypercholesterolemiaClinica Chimica Acta, 2018
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease RisksJAMA Cardiology, 2018
- Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery DiseaseJAMA, 2017
- Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trialAtherosclerosis, 2016
- Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed DyslipidemiaClinical Therapeutics, 2016
- Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid ProfileJAMA, 2013
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart DiseaseJACC, 2013